research Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report
Upadacitinib successfully treated a child's severe skin and hair loss issues.
Search
for
Sort by
Research
180-210 / 1000+ results
research The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites
Juniperus plants contain compounds with potential for developing various medical treatments.
research Follow-up
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 is generally safe for treating alopecia areata.
research Pulsed dye laser treatment of Jessner lymphocytic infiltration of the skin
Pulsed dye laser treatment was effective for a skin condition resistant to other treatments.
research The Pharmacological Potential of Bioactive Components of Zizypus jujuba Seeds: A Review
Jujube seeds have many health benefits and could be a valuable natural remedy.
research The new era of JAK inhibitors: Impelling updates in Alopecia Areata Guideline
research Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience
Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
research In-Depth Exploration of Chemical Constituents from Justicia procumbens L. Through UHPLC-Q-Exactive Orbitrap Mass Spectrometry
132 compounds were found in Justicia procumbens L., including 77 new ones.
research Effects of Jujuba essential oil on hair follicle of the skin of Balb/c mice
Jujube essential oil promotes hair growth.
research 42008 Long Term Hematologic Laboratory Safety of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research The BJUI 's clinical trials initiative
The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
JAK inhibitors helped treat hair loss in two people with Down syndrome.
research Soulflower Coupon Code – Get 25% OFF
research Soulflower Coupon Code – Get 25% OFF
research Ruxolitinib: A novel molecule in the management of dermatological disorders
Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
research Scalp and face
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
research Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis
A medication for skin rash also unexpectedly treated hair loss in a patient.
research Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.
research JAK Inhibitors in Down Syndrome: Alopecia Areata Resolution and Vitiligo Improvement with Baricitinib
Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.
research Publications from Juntendo University Graduate School of Medicine, 2018 [1/6]
The document's conclusion cannot be determined as the content is not available.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.
research JAMA Dermatology—The Year in Review, 2021
In 2021, JAMA Dermatology published significant findings on skin conditions post-COVID vaccination, melanoma surveillance, atopic dermatitis treatments, and confirmed that sun protection does not harm bone health.
research Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
research Turning JAK STATic, a peek into the future of dermatology therapeutics
JAK inhibitors show promise for treating skin diseases effectively and safely.
research A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research Case of non-Herlitz junctional epidermolysis bullosa withCOL17A1mutation
Genetic testing is crucial for diagnosing and managing non-Herlitz junctional epidermolysis bullosa.